Study title:
A single dose, randomised, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of FormoterolHFA pMDI 12 mg per actuation administered by means of a "spacer"device (AeroChamber PlusTM) with that of Formoterol-HFA pMDI 12 mg per actuation in 5 to 12 yesar old children with persistent moderate to severe asthma.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Respiratory Tract Diseases
|
Brands: |
MAH holders: Please see report, Please see report |
Assessment: |
Active substance: FORMOTEROL |
ATC code: R03AC13 |
Document link:
CCD-0602-RS-0004 (Synopsis).doc
|
Document date: 2015-03-02
|
Study number: DM-PR-3301-003-05
|
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|